Research programme: hepatitis C virus NS4b protein inhibitors - Genelabs
Latest Information Update: 02 Apr 2012
At a glance
- Originator Genelabs Technologies
- Class Imidazoles; Oxazolidinones; Pyridines; Small molecules
- Mechanism of Action Hepatitis C virus NS4 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Hepatitis C